The gamma secretase inhibitor MRK-003 attenuates pancreatic cancer growth in preclinical models

Molecular Cancer Therapeutics

Volumn 11, Issue 9, 2012, Pages 1999-2009

  Mizuma, Masamichi ^a,c   Rasheed, Zeshaan A ^a   Yabuuchi, Shinichi ^a   Omura, Noriyuki ^a   Campbell, Nathaniel R ^a   De Wilde, Roeland F ^a   De Oliveira, Elizabeth ^a   Zhang, Qing ^b   Puig, Oscar ^b   Matsui, William ^a   Hidalgo, Manuel ^a   Maitra, Anirban ^a   Rajeshkumar, N V ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

^c TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; B LYMPHOCYTE RECEPTOR; GAMMA SECRETASE INHIBITOR; GEMCITABINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; KI 67 ANTIGEN; MRK 003; NOTCH1 RECEPTOR; TRANSCRIPTION FACTOR NF E2; UNCLASSIFIED DRUG;

ANCHORAGE INDEPENDENT GROWTH; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER MODEL; CANCER STEM CELL; CELL RENEWAL; CONTROLLED STUDY; DRUG POTENCY; DRUG POTENTIATION; DRUG RESPONSE; DRUG SENSITIVITY; DRUG TARGETING; FLUORESCENCE ACTIVATED CELL SORTING; FLUORESCENCE MICROSCOPY; GENE EXPRESSION; HISTOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MONOTHERAPY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; PROTEIN DOMAIN; REAL TIME POLYMERASE CHAIN REACTION; RECEPTOR DOWN REGULATION; RECEPTOR UPREGULATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TUMOR ENGRAFTMENT; TUMOR NECROSIS; TUMOR XENOGRAFT; WESTERN BLOTTING;

AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL ADHESION; CELL LINE, TUMOR; CELL NUCLEUS; CELL PROLIFERATION; CYCLIC S-OXIDES; DEOXYCYTIDINE; DRUG SYNERGISM; GENE EXPRESSION; HUMANS; MALE; MICE; MICE, NUDE; NEOPLASTIC STEM CELLS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PANCREATIC NEOPLASMS; RECEPTOR, NOTCH1; THIADIAZOLES; TRANSCRIPTOME; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84866064437     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-12-0017     Document Type: Article

References (44)

1. Vincent A, Herman J, Schulick R, Hruban RH, Goggins M. Pancreatic cancer. Lancet 2011;378:607-20.
2. Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011;364:1817-25.
3. Saif MW, Chabot J. Chemotherapy: metastatic pancreatic cancer - is FOLFIRINOX the new standard? Nat Rev Clin Oncol 2011;8:452-3.
4. Kopan R, Ilagan MX. The canonicalNotch signaling pathway: unfolding the activation mechanism. Cell 2009;137:216-33.
5. Miele L, Golde T, Osborne B. Notch signaling in cancer. Curr Mol Med 2006;6:905-18. (Pubitemid 44883940)
6. Aster JC, Pear WS, Blacklow SC. Notch signaling in leukemia. Annu Rev Pathol 2008;3:587-613. (Pubitemid 351488294)
7. van Es JH, van Gijn ME, Riccio O, van den Born M, Vooijs M, Begthel H, et al. Notch/gamma-secretase inhibition turns proliferative cells in intestinal crypts and adenomas into goblet cells. Nature 2005;435:959-63. (Pubitemid 40896322)
8. Rizzo P, Osipo C, Foreman K, Golde T, Osborne B, Miele L. Rational targeting of Notch signaling in cancer. Oncogene 2008;27:5124-31.
9. Leach SD. Epithelial differentiation in pancreatic development and neoplasia: new niches for nestin and Notch. J Clin Gastroenterol 2005;39:S78-82. (Pubitemid 40397020)
10. Miyamoto Y, Maitra A, Ghosh B, Zechner U, Argani P, Iacobuzio-Donahue CA, et al. Notch mediates TGF alpha-induced changes in epithelial differentiation during pancreatic tumorigenesis. Cancer Cell 2003;3:565-76. (Pubitemid 36808651)
11. Plentz R, Park JS, Rhim AD, Abravanel D, Hezel AF, Sharma SV, et al. Inhibition of gamma-secretase activity inhibits tumor progression in a mouse model of pancreatic ductal adenocarcinoma. Gastroenterology 2009;136:1741-9.e6.
12. Mullendore ME, Koorstra JB, Li YM, Offerhaus GJ, Fan X, Henderson CM, et al. Ligand-dependent Notch signaling is involved in tumor initiation and tumor maintenance in pancreatic cancer. Clin Cancer Res 2009;15:2291-301.
13. Konishi J, Kawaguchi KS, Vo H, Haruki N, Gonzalez A, Carbone DP, et al. Gamma-secretase inhibitor prevents Notch3 activation and reduces proliferation in human lung cancers. Cancer Res 2007;67:8051-7. (Pubitemid 47395139)
14. Chen J, Kesari S, Rooney C, Strack PR, Shen H,WuL, et al. Inhibition of notch signaling blocks growth of glioblastoma cell lines and tumor neurospheres. Genes Cancer 2011;1:822-35.
15. Deangelo DJ, Stone RM, Silverman LB, Stock W, Attar EC, Fearen I, et al. A phase I clinical trial of the notch inhibitor MK-0752 in patients with T-cell acute lymphoblastic leukemia/lymphoma (T-ALL) and other leukemias. J Clin Oncol 2006;24:6585.
16. Fouladi M, Stewart CF, Olson J, Wagner LM, Onar-Thomas A, Kocak M, et al. Phase I trial of MK-0752 in children with refractory CNS malignancies: a pediatric brain tumor consortium study. J Clin Oncol 2011;29:3529-34.
17. Lewis HD, Leveridge M, Strack PR, Haldon CD, O'Neil J, Kim H, et al. Apoptosis in T cell acute lymphoblastic leukemia cells after cell cycle arrest induced by pharmacological inhibition of notch signaling. Chem Biol 2007;14:209-19. (Pubitemid 46274429)
18. Pourquier P, Gioffre C, Kohlhagen G, Urasaki Y, Goldwasser F, Hertel LW, et al. Gemcitabine (2′,2′-difluoro-2′-deoxycytidine), an antimetabolite that poisons topoisomerase I. Clin Cancer Res 2002;8:2499-504. (Pubitemid 34856331)
19. Jones S, Zhang X, Parsons DW, Lin JC, Leary RJ, Angenendt P, et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 2008;321:1801-6.
20. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 2001;25:402-8. (Pubitemid 34164012)
21. Rajeshkumar NV, De Oliveira E, Ottenhof N, Watters J, Brooks D, Demuth T, et al. MK-1775, a potent wee1 inhibitor, synergizes with gemcitabine to achieve tumor regressions, selectively in p53-deficient pancreatic cancer xenografts. Clin Cancer Res 2011;17:2799-806.
22. Rasheed ZA, Yang J, Wang Q, Kowalski J, Freed I, Murter C, et al. Prognostic significance of tumorigenic cells with mesenchymal features in pancreatic adenocarcinoma. J Natl Cancer Inst 2010;102:340- 51.
23. Rajeshkumar NV, Rasheed ZA, Garcia-Garcia E,Lopez-Rios F, Fujiwara K, Matsui WH, et al. A combination of DR5 agonistic monoclonal antibody with gemcitabine targets pancreatic cancer stem cells and results in long-termdisease control in human pancreatic cancer model. Mol Cancer Ther 2011;10:2582-92.
24. Garrido-Laguna I, Uson M, Rajeshkumar NV, Tan AC, de Oliveira E, Karikari C, et al. Tumor engraftment in nude mice and enrichment in stroma- related gene pathways predict poor survival and resistance to gemcitabine in patients with pancreatic cancer. Clin Cancer Res 2011;17:5793-800.
25. Pramanik D, Campbell NR, Karikari C, Chivukula R, Kent OA, Mendell JT, et al. Restitution of tumor suppressor microRNAs using a systemic nanovector inhibits pancreatic cancer growth in mice.Mol Cancer Ther 2011;10:1470-80.
26. Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U, et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 2003;4:249-64.
27. Li C, Heidt DG, Dalerba P, Burant CF, Zhang L, Adsay V, et al. Identification of pancreatic cancer stem cells. Cancer Res 2007;67:1030- 7.
28. He HH, Meyer CA, Shin H, Bailey ST, Wei G,WangQ, et al. Nucleosome dynamics define transcriptional enhancers. Nat Genet 2010;42:343-7.
29. Kheirallah S, Caron P, Gross E, Quillet-Mary A, Bertrand-Michel J, Fournie JJ, et al. Rituximab inhibits B-cell receptor signaling. Blood 2010;115:985-94.
30. Maniati E, Bossard M, Cook N, Candido JB, Emami-Shahri N, Nedospasov SA, et al. Crosstalk between the canonical NF-kappaB and Notch signaling pathways inhibits Ppargamma expression and promotes pancreatic cancer progression in mice. J Clin Invest 2011;121:4685- 99.
31. Wang Z, Banerjee S, Ahmad A, Li Y, Azmi AS, Gunn JR, et al. Activated K-ras and INK4a/Arf deficiency cooperate during the development of pancreatic cancer by activation of Notch and NF-kappaB signaling pathways. PLoS One 2011;6:e20537.
32. Feldmann G, Mishra A, Bisht S, Karikari C, Garrido-Laguna I, Rasheed Z, et al. Cyclin-dependent kinase inhibitor Dinaciclib (SCH727965) inhibits pancreatic cancer growth and progression in murine xenograft models. Cancer Biol Ther 2011;12:598-609.
33. Weijzen S, Rizzo P, Braid M, Vaishnav R, Jonkheer SM, Zlobin A, et al. Activation of Notch-1 signaling maintains the neoplastic phenotype in human Ras-transformed cells. Nat Med 2002;8:979-86. (Pubitemid 35033702)
34. Fan X, Mikolaenko I, Elhassan I, Ni X, Wang Y, Ball D, et al. Notch1 and notch2 have opposite effects on embryonal brain tumor growth. Cancer Res 2004;64:7787-93. (Pubitemid 39446911)
35. Osipo C, Patel P, Rizzo P, Clementz AG, Hao L, Golde TE, et al. ErbB-2 inhibition activates Notch-1 and sensitizes breast cancer cells to a gamma-secretase inhibitor. Oncogene 2008;27:5019-32.
36. Pandya K, Meeke K, Clementz AG, Rogowski A, Roberts J, Miele L, et al. Targeting both Notch and ErbB-2 signalling pathways is required for prevention of ErbB-2-positive breast tumour recurrence. Br J Cancer 2011;105:796-806.
37. Feldmann G, Dhara S, Fendrich V, Bedja D, Beaty R, Mullendore M, et al. Blockade of hedgehog signaling inhibits pancreatic cancer invasion and metastases: a new paradigm for combination therapy in solid cancers. Cancer Res 2007;67:2187-96. (Pubitemid 46424238)
38. Cook N, Frese KK, Bapiro TE, Jacobetz MA, Gopinathan A, Miller JL, et al.Gammasecretase inhibition promotes hypoxic necrosis in mouse pancreatic ductal adenocarcinoma. J Exp Med 2012;209:437-44.
39. Wang Z, Zhang Y, Banerjee S, Li Y, Sarkar FH. Inhibition of nuclear factor kappab activity by genistein is mediated via Notch-1 signaling pathway in pancreatic cancer cells. Int J Cancer 2006;118:1930-6.
40. Wang Z, Zhang Y, Li Y, Banerjee S, Liao J, Sarkar FH. Down-regulation of Notch-1 contributes to cell growth inhibition and apoptosis in pancreatic cancer cells. Mol Cancer Ther 2006;5:483 -93.
41. He F, Wang L, Hu XB, Yin DD, Zhang P, Li GH, et al. Notch and BCR signaling synergistically promote the proliferation of Raji B-lymphoma cells. Leuk Res 2009;33:798-802.
42. Thomas M, Calamito M, Srivastava B, Maillard I, Pear WS, Allman D. Notch activity synergizes with B-cell-receptor and CD40 signaling to enhance B-cell activation. Blood 2007;109:3342-50. (Pubitemid 46572522)
43. DeNicola GM, Karreth FA, Humpton TJ, Gopinathan A, Wei C, Frese K, et al. Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis. Nature 2011;475:106-9.
44. ClinicalTrials.gov [homepage on the internet]. A service of the U.S. Natioanal Institutes of Health, Bethesda. [updated Feb 27, 2012]. Identifier NCT01098344. Available from: http://clinicaltrials.gov.